UroMems eyes regulatory filings for SUI treatment after $60m fundraise

UroMems plans to use the funds to complete a pivotal trial to support regulatory filings for its UroActive system in the US and Europe. UroMems plans to use the funds to complete a pivotal trial to support regulatory filings for its UroActive system in the US and Europe. SUI, or involuntary urinary leakage, affects an estimated 40 million Americans and 90 million Europeans. Credit: CI Photos / Shutterstock.com UroMems has raised $60m, priming the French company to complete a pivotal trial of its stress urinary incontinence (SUI) treatment, the data from which will support regulatory filings for the implant in…

Source: Medical Device Network